Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.53 -2.5%	$2.21	$1.09 ▼ $3.40	$174.31M	0.61	741,961 shs	263,829 shs
IMVT Immunovant	$33.62 +2.3%	$29.25	$14.32 ▼ $36.28	$6.75B	0.76	2.52 million shs	1.14 million shs
KRYS Krystal Biotech	$317.97 -1.1%	$288.44	$127.99 ▼ $331.49	$9.48B	0.53	236,000 shs	291,320 shs
OCGN Ocugen	$1.21 -0.8%	$1.54	$0.90 ▼ $2.73	$413M	2.19	4.96 million shs	3.73 million shs
RGNX REGENXBIO	$6.66 +6.1%	$7.98	$5.45 ▼ $16.19	$324.66M	1.04	1.67 million shs	903,377 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-2.24%	-6.42%	-28.84%	-30.45%	-6.13%
IMVT Immunovant	+2.25%	+8.07%	+14.94%	+37.73%	+108.17%
KRYS Krystal Biotech	-1.11%	+5.64%	+1.72%	+28.60%	+127.74%
OCGN Ocugen	-0.82%	-5.47%	-17.69%	-51.21%	+4.31%
RGNX REGENXBIO	+6.05%	+9.54%	-33.67%	-22.29%	-34.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.53 -2.5%	$2.21	$1.09 ▼ $3.40	$174.31M	0.61	741,961 shs	263,829 shs
IMVT Immunovant	$33.62 +2.3%	$29.25	$14.32 ▼ $36.28	$6.75B	0.76	2.52 million shs	1.14 million shs
KRYS Krystal Biotech	$317.97 -1.1%	$288.44	$127.99 ▼ $331.49	$9.48B	0.53	236,000 shs	291,320 shs
OCGN Ocugen	$1.21 -0.8%	$1.54	$0.90 ▼ $2.73	$413M	2.19	4.96 million shs	3.73 million shs
RGNX REGENXBIO	$6.66 +6.1%	$7.98	$5.45 ▼ $16.19	$324.66M	1.04	1.67 million shs	903,377 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-2.24%	-6.42%	-28.84%	-30.45%	-6.13%
IMVT Immunovant	+2.25%	+8.07%	+14.94%	+37.73%	+108.17%
KRYS Krystal Biotech	-1.11%	+5.64%	+1.72%	+28.60%	+127.74%
OCGN Ocugen	-0.82%	-5.47%	-17.69%	-51.21%	+4.31%
RGNX REGENXBIO	+6.05%	+9.54%	-33.67%	-22.29%	-34.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	136.93% Upside
IMVT Immunovant	2.45	Hold	$37.33	11.05% Upside
KRYS Krystal Biotech	2.83	Moderate Buy	$324.11	1.93% Upside
OCGN Ocugen	2.60	Moderate Buy	$9.50	685.12% Upside
RGNX REGENXBIO	2.73	Moderate Buy	$23.55	253.54% Upside

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/8/2026	RGNX REGENXBIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/5/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $26.00
6/2/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/1/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$310.00
5/27/2026	OCGN Ocugen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $11.00
5/26/2026	IMVT Immunovant	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $62.00
5/22/2026	IMVT Immunovant	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$23.00 ➝ $30.00
5/21/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/21/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $40.00
5/21/2026	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $43.00
5/18/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	8.07	N/A	N/A	$0.28 per share	5.46
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KRYS Krystal Biotech	$389.13M	24.09	$7.21 per share	44.11	$42.06 per share	7.56
OCGN Ocugen	$4.41M	92.88	N/A	N/A	($0.04) per share	-30.25
RGNX REGENXBIO	$170.44M	2.02	N/A	N/A	$2.03 per share	3.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.19	N/A	N/A	N/A	-680.83%	-295.17%	-40.95%	8/6/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.78	N/A	N/A	N/A	N/A	-65.66%	-59.88%	8/10/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.48	42.51	30.23	N/A	53.92%	19.25%	17.62%	8/3/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.24	N/A	N/A	N/A	-1,192.18%	-127,987.80%	-135.48%	7/30/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$5.60	N/A	N/A	N/A	-330.23%	-232.50%	-61.02%	8/6/2026 (Estimated)

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2026	Q4 2026	IMVT Immunovant	-$0.60	-$0.73	-$0.13	-$0.73	N/A	N/A
5/14/2026	Q1 2026	RGNX REGENXBIO	-$1.36	-$1.72	-$0.36	-$1.72	$25.84 million	$6.39 million
5/7/2026	Q1 2026	ALEC Alector	-$0.2878	-$0.21	+$0.0778	-$0.21	$9.67 million	$1.05 million
5/5/2026	Q1 2026	OCGN Ocugen	-$0.05	-$0.06	-$0.01	-$0.06	$0.42 million	$1.53 million
5/4/2026	Q1 2026	KRYS Krystal Biotech	$1.45	$1.83	+$0.38	$1.83	$112.11 million	$116.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.25	5.25
IMVT Immunovant	N/A	9.09	9.09
KRYS Krystal Biotech	N/A	9.46	9.06
OCGN Ocugen	4.17	1.86	1.86
RGNX REGENXBIO	N/A	2.62	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
IMVT Immunovant	47.08%
KRYS Krystal Biotech	86.29%
OCGN Ocugen	10.27%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
IMVT Immunovant	1.80%
KRYS Krystal Biotech	13.10%
OCGN Ocugen	3.95%
RGNX REGENXBIO	14.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.03 million	101.81 million	Optionable
IMVT Immunovant	120	205.31 million	201.61 million	Optionable
KRYS Krystal Biotech	210	29.48 million	25.62 million	Optionable
OCGN Ocugen	80	338.52 million	325.15 million	Optionable
RGNX REGENXBIO	370	51.70 million	44.35 million	Optionable

ALEC, RGNX, KRYS, IMVT, and OCGN Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for REGENXBIO Q3 Earnings?

June 8, 2026 | americanbankingnews.com

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)

June 6, 2026 | theglobeandmail.com

How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary

June 2, 2026 | finance.yahoo.com

REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 22, 2026 | seekingalpha.com

REGENXBIO to Participate in Upcoming Investor Conferences

May 18, 2026 | prnewswire.com

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate

May 18, 2026 | genengnews.comG

Regenxbio (RGNX) Q1 2026 Earnings Transcript

May 18, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)

May 17, 2026 | theglobeandmail.com

Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results

May 17, 2026 | seekingalpha.com

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

May 15, 2026 | marketbeat.com

Regenxbio: Q1 Earnings Snapshot

May 15, 2026 | stamfordadvocate.comS

RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success

May 15, 2026 | msn.com

REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Regenxbio's muscle disorder therapy meets main goal in late-stage study

May 14, 2026 | msn.com

Regenxbio slides after late-stage trial data for Duchenne therapy

May 14, 2026 | seekingalpha.com

Regenxbio Shares Rise After Positive Duchenne Trial Results

May 14, 2026 | finance.yahoo.com

Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...

May 14, 2026 | finance.yahoo.com

REGENXBIO (NASDAQ:RGNX) Releases Earnings Results, Misses Estimates By $0.38 EPS

May 14, 2026 | marketbeat.com

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

May 14, 2026 | benzinga.com

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

May 14, 2026 | zacks.com

Insider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells 15,309 Shares of Stock

May 14, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, RGNX, KRYS, IMVT, and OCGN Company Descriptions

Alector NASDAQ:ALEC

$1.53 -0.04 (-2.55%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.52%)

As of 06/12/2026 07:22 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Immunovant NASDAQ:IMVT

$33.62 +0.74 (+2.25%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$33.67 +0.05 (+0.16%)

As of 06/12/2026 07:48 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Krystal Biotech NASDAQ:KRYS

$317.97 -3.58 (-1.11%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$318.50 +0.53 (+0.17%)

As of 06/12/2026 07:59 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Ocugen NASDAQ:OCGN

$1.21 -0.01 (-0.82%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.41%)

As of 06/12/2026 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

REGENXBIO NASDAQ:RGNX

$6.66 +0.38 (+6.05%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$6.57 -0.09 (-1.35%)

As of 06/12/2026 07:27 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, RGNX, KRYS, IMVT, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, RGNX, KRYS, IMVT, and OCGN Company Descriptions

Alector NASDAQ:ALEC

Immunovant NASDAQ:IMVT

Krystal Biotech NASDAQ:KRYS

Ocugen NASDAQ:OCGN

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, RGNX, KRYS, IMVT, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, RGNX, KRYS, IMVT, and OCGN Company Descriptions

Alector NASDAQ:ALEC

Immunovant NASDAQ:IMVT

Krystal Biotech NASDAQ:KRYS

Ocugen NASDAQ:OCGN

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools